Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Decline in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the target of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 49,958 shares, a decrease of 32.3% from the July 30th total of 73,790 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 50,520 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Several research firms have commented on DWTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Trading Up 3.5%

Shares of NASDAQ:DWTX traded up $0.09 on Tuesday, reaching $2.67. 91,382 shares of the company traded hands, compared to its average volume of 77,845. The stock has a market capitalization of $90.79 million, a P/E ratio of -0.29 and a beta of 1.71. The business’s 50-day simple moving average is $1.77 and its 200 day simple moving average is $1.99. Dogwood Therapeutics has a 52 week low of $1.28 and a 52 week high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.20). Sell-side analysts expect that Dogwood Therapeutics will post -0.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.